(Q61957229)
Statements
A Multicenter, Open-label, Single-arm, 24 Week Phase IV Study Evaluating the Effectiveness and Safety of Treatment of Insulin Glargine in Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 (GLP-1) Failure (English)
0 references
November 2011
0 references
December 2012
0 references
89
0 references
30 year
0 references
75 year
0 references